Full Press Release Details
CGuard Carotid Embolic Prevention System
Featured in Live Case Transmission at EuroPCR 2017
Alberto Cremonesi's team performed successful case
treating a patient with carotid artery disease with CGuard
Aviv, Israel - May 18, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the "Company"),
a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that
the team of Prof. Alberto Cremonesi, Chief of the Cardiovascular Department and Director of the Interventional Cardiovascular
Unit of Maria Cecilia Hospital - GVM Care & Research, Cotignola (Italy), performed a live stent endovascular interventional
procedure featuring the CGuard EPS Carotid Stent at EuroPCR 2017. The case was transmitted real time to the entire congress.
Dr. Cremonesi is one of the Course Directors of EuroPCR.
Cremonesi commented, "The CGuard EPS Carotid Stent performance was excellent and lived up to our expectations. It
will be an important tool in the treatment paradigm for carotid artery disease as the carotid artery stenting procedure becomes
an increasingly viable alternative to carotid artery endarterectomy/surgery in Europe."
is the official annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the world-leading
course in interventional cardiovascular medicine. Bringing together over 12,000 clinicians and industry executives each year,
EuroPCR is the global forum for sharing within and between all interventional communities. EuroPCR 2017 is taking place from 16-19
one of the leading interventional cardiologists in Europe, we are truly honored and grateful to have Dr. Cremonesi and his team
perform a live broadcast case treating a patient with carotid artery disease using CGuardTM at EuroPCR," said
James Barry, PhD, Chief Executive Officer of InspireMD."
E-poster by Prof. Piotr Musialek, MD, DPhil, FESC, from the Jagiellonian University Department of Cardiac & Vascular Diseases
was accepted and exhibited at EuroPCR 2017.
poster is entitled "Durability of stroke prevention using routinely the CGuard MicroNet covered embolic
prevention stent system to perform carotid revascularization in symptomatic and increased-stroke-risk asymptomatic patients: 12-month
prospective evidence from PARADIGM study." It is on show May 16 - May 19, 2017 at EuroPCR 2017.
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection
and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization,
no reflow and major adverse cardiac events.
intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard ), neurovascular, and peripheral
artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR and certain warrants
are quoted on the NYSE MKT under the ticker symbol NSPR.WS.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot
be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance
of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability
to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much
larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities
and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third
party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering
our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need
to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive
or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign
currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws
and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors
that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information,
future events or otherwise.